Details:

Alternative Title:
Intramuscular Shingrix vaccination infographic
Corporate Authors:
National Center for Immunization and Respiratory Diseases (U.S.)
Description:
Recombinant Zoster Vaccine (Shingrix)

Using Shingrix vaccine

KNOW THE SITE. GET IT RIGHT!

Store and Prepare the Vaccine

• Store Shingrix vaccine (recombinant zoster vaccine) AND adjuvanted diluent in the refrigerator between 2°C and 8°C (36°F and 46°F).

• Store in original packaging, protected from light.

• DO NOT FREEZE. Frozen vaccine or adjuvanted diluent should NOT be administered.

• Prepare vaccine just before administration using a new, sterile needle and syringe.

• Reconstitute vaccine with the adjuvanted diluent that came with the lyophilized vaccine.

IM injection best practices

• Identify the site carefully using anatomical landmarks. Shoulder injury related to vaccine administration (SIRVA) may result from the unintentional injection of a vaccine into tissues and structures lying underneath the deltoid muscle.

• Administering the injection too high on the upper arm may cause shoulder injury.

Administer the vaccine correctly

• Route: Intramuscular (IM) injection

• Needle: 23-25 gauge, 1 to 1 1/2 inch sterile needle

• Dose: 5 mL

• Site: Deltoid muscle

• Administration: May administer during the same clinical visit as other needed vaccines. Administer in a separate limb from other vaccines, if possible.

Follow the schedule

• CDC recommends Shingrix as preferred over Zostavax® (zoster vaccine live) for the prevention of herpes zoster (shingles) and related complications.*

• Shingrix vaccine is a 2-dose series, administered 2 to 6 months apart. Both doses are needed to provide protection.

• Shingrix is recommended for individuals 50 years of age and older.

• Shingrix can be administered to people who have received Zostavax or have already had shingles.

• If Zostavax was previously given, wait at least 8 weeks before administering Shingrix.

• Schedule an appointment for the second dose before the patient leaves.

Educate the patient

• About 1 out of 6 people who got Shingrix experienced side effects that prevented them from doing regular activities for a few days.

• Remind patients they may experience a local reaction or side effect such as pain, redness, and swelling and systemic reactions such as myalgia, fatigue, and headache that may interrupt regular activities a few days after receiving Shingrix.

• It is important patients get the second dose of Shingrix to build strong protection against shingles, even if they have side effects from the first dose.

• Patients’ reactions to each dose may be different; just because they have a reaction to the first dose does not mean they will have a reaction to the second.

For additional information on proper vaccine administration, visit the CDC vaccine administration web page at https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html

*Zostavax® is still recommended for healthy adults 60 years and older. Learn more about Zostavax https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/index.html.

Report any clinically significant adverse event after vaccination to the Vaccine Adverse Event Reporting System (VAERS) at vaers.hhs.gov

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention

CS249275-BE

Called also: Intramuscular Shingrix vaccination infographic

call-the-shots-Shingrix-P_508.pdf

Publication date from document properties.


Subjects:
[+]
Adult Herpes Zoster Herpes Zoster Vaccine Injections, Intramuscular
Document Type:
Poster
Genre:
Infographic
Collection(s):
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:b2d9c132e969c2ff6a2c295072cc27293e7afa4fad1369cfdc683ca1f83d8702
Download URL:
https://stacks.cdc.gov/view/cdc/56362/cdc_56362_DS1.pdf
File Type:

Supporting Files

• No Additional Files

More +